Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Protalix BioTherapeutics, Inc.AMEX: PLX

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 48.7% from a year ago

Total equity stood at $67.23M at the end of Q1 FY2026, up 48.7% from a year earlier and up 39.4% from the prior quarter.

Context

  • Total equity amounted to 65.7% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +48.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67.23M+39.4% QoQ
Last fiscal yearDec 2025
$48.23M+11.6% YoY
Year agoMar 2025
$45.21M+48.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.7%——
1 year+11.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
48.23M USD
Year-over-year change
+11.6%

Total Equity vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's Mar 2026 total equity of $67.23M is the 2nd highest of the 4 companies compared; the peer median is $2.49M.
  • Its year-over-year change of +48.7% is the highest of 4, against a peer median of -41.5%.
  • Total equity amounts to 65.7% of total assets for PLX, versus a peer median of 55.0%.
PLX Competitors Peer median
Total Equity for PLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PHARPharming Group N.V.Mar 2026$268.96M +24.9%+10.6%55.0%
PLXProtalix BioTherapeutics, Inc.Mar 2026$67.23M +48.7%—65.7%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$2.49M -41.5%—71.0%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$229M -251.4%—17.7%
Peer median (excluding PLX) $2.49M-41.5%+10.6%55.0%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.99M17.11M23.63M19.76M14.68M
Short-term Investments05.07M20.93M15.07M15.59M
Net Receivables3.44M4.59M5.27M2.91M8.84M
Inventory17.95M16.8M19.05M21.24M25.73M
Other Current Assets380K536K611K596K1.44M
Total Current Assets61.67M44.88M69.93M60.08M66.67M
Property, Plant & Equipment (Net)9.92M9.64M10.88M10.02M12.58M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets003.09M2.86M2.52M
Other Non-current Assets2.08M1.27M528K462K578K
Total Non-current Assets12M10.91M14.5M13.34M15.67M
Total Assets73.67M55.79M84.43M73.42M82.35M
Account Payables6.99M5.86M4.32M4.53M5.26M
Short-term Debt0021.66M00
Tax Payables0530K2.88M3.48M0
Deferred Revenue8.55M13.18M000
Other Current Liabilities1.51M11.06M4.94M1.81M2.31M
Total Current Liabilities33.18M32.43M45.53M25.62M26.52M
Long-term Debt27.89M28.19M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)11.79M0000
Other Non-current Liabilities2.47M1.64M714K559K661K
Total Non-current Liabilities46.53M34M5.34M4.59M7.6M
Total Liabilities79.7M66.43M50.87M30.21M34.12M
Common Stock46K54K73K76K80K
Retained Earnings(374.93M)(389.86M)(381.55M)(378.39M)(385M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(6.04M)(10.64M)33.57M43.21M48.23M
Total Debt33.47M33.47M27.69M5.53M8.32M
Net Debt(5.52M)16.36M4.06M(14.23M)(6.36M)

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.